Gemcitabine

製品コードS1714 別名:LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW):263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00

カスタマーフィードバック(4)

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NXTqNYFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDSTWM2OD1yLkCwNFQ2QCCwTR?= MlrSV2FPT0WU
ES4 M2DNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX2V4tKSzVyPUCuNFAxPjV|IH7N NX61UI1DW0GQR1XS
ACHN M3izd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnPTWM2OD1yLkCwNFg5PyCwTR?= MnzuV2FPT0WU
KYSE-510 NXnoZ2E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;QTWM2OD1yLkCwNFk4PSCwTR?= MmrPV2FPT0WU
EW-7 NH7adJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC3S49KSzVyPUCuNFAzPThibl2= MWLTRW5ITVJ?
BFTC-905 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEC1NVUhdk1? MlizV2FPT0WU
KE-37 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H1fmlEPTB;MD6wNFU3OSCwTR?= NUDSUJNYW0GQR1XS
SBC-5 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrXfVFKSzVyPUCuNFA2PyCwTR?= MnrkV2FPT0WU
NKM-1 NULyZYNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPmSllKSzVyPUCuNFA4ODlibl2= NIKyXVlUSU6JRWK=
RH-1 M2HpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT2TWM2OD1yLkCwO|E5KG6P MUXTRW5ITVJ?
ALL-PO NFnkbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKzTWM2OD1yLkCwPFMhdk1? NVnr[I1sW0GQR1XS
QIMR-WIL NYLtTIZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v2b2lEPTB;MD6wNFg6PCCwTR?= M3XpPXNCVkeHUh?=
A375 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fqc2lEPTB;MD6wNFk6PSCwTR?= NFKyOotUSU6JRWK=
SIG-M5 NVnTZ4Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzpdHRKSzVyPUCuNFExPCCwTR?= M{DiTHNCVkeHUh?=
KGN M4nhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\veGlEPTB;MD6wNVA5KG6P MoP6V2FPT0WU
EW-13 NEfNcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTiTWM2OD1yLkCxNVIhdk1? MXzTRW5ITVJ?
NCI-SNU-1 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXpWWJKSzVyPUCuNFE3KG6P MV3TRW5ITVJ?
PSN1 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknUTWM2OD1yLkCxOlUhdk1? NELER5RUSU6JRWK=
HUTU-80 M2qzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS1fJBKSzVyPUCuNFE3PiCwTR?= M2fsc3NCVkeHUh?=
EW-16 M2DxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPM[nhTUUN3ME2wMlAzOyCwTR?= MVXTRW5ITVJ?
786-0 MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLSTWM2OD1yLkCyN{BvVQ>? MlnHV2FPT0WU
ES1 NUf3[4NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe5XZRKSzVyPUCuNFI3QCCwTR?= MYHTRW5ITVJ?
RKO M3PpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPjVpNLUUN3ME2wMlAzPzlibl2= M3;SVHNCVkeHUh?=
ESS-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jmdGlEPTB;MD6wNlg3KG6P M372PHNCVkeHUh?=
SK-UT-1 M{DmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX5TWM2OD1yLkCyPVchdk1? NWnMWZBmW0GQR1XS
LB2241-RCC NXXmUIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS1TWM2OD1yLkCzNVghdk1? MYHTRW5ITVJ?
CHL-1 NEjld4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPs[IhqUUN3ME2wMlA{OjRibl2= Mn\2V2FPT0WU
SW1783 M1m0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHDTlVqUUN3ME2wMlA{OzZibl2= NIj4N5hUSU6JRWK=
MEL-JUSO M1LLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPNNoFDUUN3ME2wMlA{QTFibl2= NW[4ZlBXW0GQR1XS
HT-29 M2HscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GxTmlEPTB;MD6wOFE{KG6P M3PvS3NCVkeHUh?=
SNG-M M{nTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvMepFKUUN3ME2wMlA1OjVibl2= Mnu4V2FPT0WU
TE-15 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\iOWlEPTB;MD6wOFY1KG6P MVXTRW5ITVJ?
HOS MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMES4JI5O NETkOmJUSU6JRWK=
BB65-RCC MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3TTWM2OD1yLkC1NVIhdk1? M{LFb3NCVkeHUh?=
HCE-4 NYfycFRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXzTWM2OD1yLkC1Nlghdk1? MkfIV2FPT0WU
MHH-ES-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrMXFVKSzVyPUCuNFU{OSCwTR?= MUTTRW5ITVJ?
RPMI-7951 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnkeodKSzVyPUCuNFU1OSCwTR?= NYDYZo9WW0GQR1XS
IST-SL2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L4W2lEPTB;MD6wOVg1KG6P MUTTRW5ITVJ?
CMK NVTrVFBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDoeIF{UUN3ME2wMlA2QDZibl2= MVfTRW5ITVJ?
GR-ST MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nGb2lEPTB;MD6wOVk2KG6P NGDuNYdUSU6JRWK=
NALM-6 M2HsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHrTnlKSzVyPUCuNFYzOiCwTR?= NHno[GJUSU6JRWK=
RPMI-6666 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nqdGlEPTB;MD6wOlUzKG6P Mle1V2FPT0WU
LC-2-ad NHjwbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrUR3FpUUN3ME2wMlA3PTNibl2= M3m2WXNCVkeHUh?=
ARH-77 NGT1U2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMEexNUBvVQ>? NGG1dohUSU6JRWK=
IST-MEL1 M13ZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMEeyOkBvVQ>? MlrHV2FPT0WU
SW1710 M3vYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\nUYQ3UUN3ME2wMlA4PTFibl2= NX;MPYNOW0GQR1XS
DEL M3\jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjMVYRsUUN3ME2wMlA5QDdibl2= NHP5O2tUSU6JRWK=
AGS NEHBco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LuVWlEPTB;MD6wPVAzKG6P MUPTRW5ITVJ?
NCI-H2122 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEm0OkBvVQ>? NWDWVJQzW0GQR1XS
HSC-4 NYOzN4hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHJTWM2OD1yLkGwNkBvVQ>? MlPDV2FPT0WU
AM-38 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfld2lKSzVyPUCuNVIyKG6P M{LFS3NCVkeHUh?=
769-P NXHDe5hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\0eIdKSzVyPUCuNVI{KG6P MXfTRW5ITVJ?
RT-112 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\nbGlEPTB;MD6xNlchdk1? MmH2V2FPT0WU
MCF7 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O4SWlEPTB;MD6xN|Yhdk1? M3u5cnNCVkeHUh?=
IGROV-1 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XNWWlEPTB;MD6xOFUhdk1? MUjTRW5ITVJ?
OCI-AML2 NHnpd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfaTWM2OD1yLkG0O{BvVQ>? MYTTRW5ITVJ?
NCI-H1299 NYTleI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzy[m1bUUN3ME2wMlE2PyCwTR?= NGjSe5pUSU6JRWK=
A431 NGrufW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;GWpZ[UUN3ME2wMlE5OyCwTR?= MVTTRW5ITVJ?
SW982 NHewdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnVVWhTUUN3ME2wMlIyOyCwTR?= M4rvc3NCVkeHUh?=
BB30-HNC MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfZN5RKSzVyPUCuNlMyKG6P Mli0V2FPT0WU
ACN NIPuRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml21TWM2OD1yLkK0OEBvVQ>? M1LJXnNCVkeHUh?=
647-V NIm3c2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv0OmlwUUN3ME2wMlI1QCCwTR?= MXrTRW5ITVJ?
SK-PN-DW NVHrNlRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMk[2JI5O NED0dJJUSU6JRWK=
LCLC-97TM1 NF34VXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjVTWM2OD1yLkK2O{BvVQ>? NIX1b|lUSU6JRWK=
LB1047-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HXU2lEPTB;MD6yOlkhdk1? MUHTRW5ITVJ?
A2780 NWTIOJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLaUm9KSzVyPUCuNlchdk1? MWfTRW5ITVJ?
C-33-A MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMkezJI5O NGLRVZhUSU6JRWK=
NCI-H2228 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\hTWM2OD1yLkOxOEBvVQ>? M1rMNnNCVkeHUh?=
TE-5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCxfog2UUN3ME2wMlMyPiCwTR?= NFfGbY9USU6JRWK=
HC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwM{K3JI5O MW\TRW5ITVJ?
SK-MES-1 NUC0bZlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDqTWM2OD1yLkOyPEBvVQ>? MmGzV2FPT0WU
NCI-H1355 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:1XYJKSzVyPUCuN|gyKG6P NGP1VZBUSU6JRWK=
YKG-1 NEm4eopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jNSmlEPTB;MD60NVkhdk1? M2f1PXNCVkeHUh?=
RS4-11 NXXrUW5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwNEOzJI5O Ml[0V2FPT0WU
Daoy NIT1WZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNEW2JI5O MVfTRW5ITVJ?
A3-KAW NWGzcXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[2RpRCUUN3ME2wMlU2OSCwTR?= MX3TRW5ITVJ?
SK-MEL-30 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\uUm54UUN3ME2wMlU2PCCwTR?= MlfKV2FPT0WU
U031 NHvoUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwNU[1JI5O NWrLN2FIW0GQR1XS
SK-LMS-1 NETESJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7ubYJKSzVyPUCuOVc5KG6P MmPiV2FPT0WU
ES6 NXXOV5BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTiWHhKSzVyPUCuOVg3KG6P M1zkRXNCVkeHUh?=
EoL-1-cell NXTvZXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjNSoJHUUN3ME2wMlYyPiCwTR?= NUPob3RuW0GQR1XS
NCI-H2009 NX3RbpZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwNkG5JI5O M4DJcHNCVkeHUh?=
A4-Fuk M2fwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXSTWM2OD1yLk[yOkBvVQ>? M1Pqd3NCVkeHUh?=
KYSE-270 Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV20dFVoUUN3ME2wMlY{PCCwTR?= MVfTRW5ITVJ?
SK-LU-1 MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorsTWM2OD1yLk[1OUBvVQ>? NHfmT5BUSU6JRWK=
SW872 M372WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7HUYpKSzVyPUCuO|Y2KG6P NYLFPVBIW0GQR1XS
ES8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTDTWM2OD1yLke4JI5O M4OzS3NCVkeHUh?=
G-402 NV;rbXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwN{i0JI5O MljEV2FPT0WU
ATN-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwOEC3JI5O MXXTRW5ITVJ?
DoTc2-4510 Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwOUCxJI5O M{jhNHNCVkeHUh?=
MES-SA NHfiNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm4SIFUUUN3ME2wMlkxPSCwTR?= MUTTRW5ITVJ?
SF268 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj0dVhJUUN3ME2wMlkzPyCwTR?= NE[yOpRUSU6JRWK=
SF539 NXX2UnJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\NTWM2OD1zLkCyJI5O MXXTRW5ITVJ?
NB69 NIXYdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISyS2hKSzVyPUGuNFUhdk1? NYr0WWRxW0GQR1XS
8505C MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHtNmZKSzVyPUGuNFYhdk1? NFXwS2lUSU6JRWK=
CAL-12T NGHtNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS0TWM2OD1zLkC4JI5O M3XvNHNCVkeHUh?=
BHY M133Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\MdotmUUN3ME2xMlE1KG6P MknuV2FPT0WU
LB647-SCLC NHHlNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnUZYhnUUN3ME2xMlE5KG6P MnvaV2FPT0WU
CAL-62 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;4S2xKSzVyPUGuNlIhdk1? NVn6SWRzW0GQR1XS
MEG-01 NYXrNmE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXWTXRKSzVyPUGuNlchdk1? M2jFbHNCVkeHUh?=
MG-63 M3LRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fkeGlEPTB;MT6zN{BvVQ>? MnnuV2FPT0WU
SW620 NIDOcnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwM{Wgcm0> MkLkV2FPT0WU
A388 M2S0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe5TYlKSzVyPUGuN|Yhdk1? MUDTRW5ITVJ?
BCPAP NHWyV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITPSJdKSzVyPUGuOFUhdk1? NUmzdZE1W0GQR1XS
P30-OHK MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\RTWM2OD1zLkS2JI5O MnrMV2FPT0WU
Ca9-22 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vlTmlEPTB;MT61OEBvVQ>? M3LhcnNCVkeHUh?=
VMRC-RCZ NVLQOlNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zWbGlEPTB;MT61OEBvVQ>? MkD2V2FPT0WU
LOXIMVI NH7KeGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwNjDuUS=> MULTRW5ITVJ?
L-540 NY\YWJM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C5XWlEPTB;MT62JI5O NWHhO4p1W0GQR1XS
NTERA-S-cl-D1 NV24WJRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXWTWM2OD1zLk[0JI5O NGn6Zm5USU6JRWK=
MFH-ino NXPIWIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPJbndKSzVyPUGuOlYhdk1? MWnTRW5ITVJ?
Calu-6 M4PydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwN{Ogcm0> Ml\LV2FPT0WU
HEL MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwN{mgcm0> M1rrVXNCVkeHUh?=
CAL-33 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwOEmgcm0> MomwV2FPT0WU
HSC-3 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnvTWM2OD1zLkmxJI5O MWfTRW5ITVJ?
KU812 NX7SSXd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHpUHNKSzVyPUGuPVEhdk1? NEDBZW5USU6JRWK=
EB2 M{i1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjZT4cxUUN3ME2yMlAyKG6P MXfTRW5ITVJ?
SR Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHGTWM2OD1{LkGyJI5O NWfGc2puW0GQR1XS
NCI-H2087 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T5WWlEPTB;Mj6xOEBvVQ>? NXzmW4o{W0GQR1XS
H4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwMUigcm0> MWPTRW5ITVJ?
EW-1 NUj3T5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jETWlEPTB;Mj6yNkBvVQ>? MVPTRW5ITVJ?
MC-IXC NX\hfXBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CwdmlEPTB;Mj6yOkBvVQ>? MVHTRW5ITVJ?
NCI-H727 NYDkXWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NViyUo1QUUN3ME2yMlUyKG6P NHvrcm9USU6JRWK=
MRK-nu-1 NGLnR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2TGlEPTB;Mj61O{BvVQ>? MnH5V2FPT0WU
COLO-668 NV;k[4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLMTWM2OD1{Lk[2JI5O MlTrV2FPT0WU
CGTH-W-1 NWDONpl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjQSoRKSzVyPUKuO|Ihdk1? M{fy[3NCVkeHUh?=
CHP-212 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTmTWM2OD1{Lke1JI5O NUeyWG9XW0GQR1XS
GI-1 NV\EfmVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XoXGlEPTB;Mj63OkBvVQ>? MXzTRW5ITVJ?
HCC1806 M3nvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PYfmlEPTB;Mj65NUBvVQ>? M1HYTnNCVkeHUh?=
HLE Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFThRYpKSzVyPUOgcm0> NXqxd4k{W0GQR1XS
HSC-2 NUCxflZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwMEOgcm0> NXPmT2ZSW0GQR1XS
DMS-273 MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7YZW04UUN3ME2zMlA4KG6P MnT6V2FPT0WU
DU-4475 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHFTWM2OD1|LkG0JI5O MXHTRW5ITVJ?
LXF-289 NG\CVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXsTWM2OD1|LkOxJI5O MYPTRW5ITVJ?
PANC-03-27 NWLtNnh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNwNUGgcm0> MWLTRW5ITVJ?
GAMG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInuZ45KSzVyPUOuO|Qhdk1? MoSxV2FPT0WU
NCI-H522 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW3WoFLUUN3ME20MlM1KG6P M{jLRXNCVkeHUh?=
SW626 NEDLem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTRwNE[gcm0> MX7TRW5ITVJ?
HT-144 NEHmOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M160UGlEPTB;ND65NkBvVQ>? NH\ucJFUSU6JRWK=
MEL-HO NHv4cJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:2PIRKSzVyPUWuNVYhdk1? MmrQV2FPT0WU
BE-13 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjKe2tKSzVyPUWuNlEhdk1? M4XneHNCVkeHUh?=
VA-ES-BJ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETtRmtKSzVyPUWuNlYhdk1? M4DWenNCVkeHUh?=
NCI-H441 NHy0Xm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPVWGlKSzVyPUWuOkBvVQ>? NHe1W2JUSU6JRWK=
KP-4 NVW5VlN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu0TWM2OD13Lk[xJI5O MVnTRW5ITVJ?
LoVo NVz3XWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGSyNnFKSzVyPUWuO|Ehdk1? MUfTRW5ITVJ?
HT-1080 NGf4TnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnZU5dxUUN3ME21Mlg{KG6P NYfXfnIxW0GQR1XS
GB-1 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTVwOESgcm0> NEjzXpNUSU6JRWK=
IA-LM MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXqOFc2UUN3ME21MlkyKG6P MmrsV2FPT0WU
8-MG-BA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXLNVVYUUN3ME21Mlk{KG6P M1HQO3NCVkeHUh?=
SK-HEP-1 M4O3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrs[21KSzVyPU[uNVQhdk1? M2PJd3NCVkeHUh?=
697 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;R[WlEPTB;Nj6yOUBvVQ>? NE\YTm1USU6JRWK=
KYSE-450 M2PXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRcmlEPTB;Nj6zNkBvVQ>? M4D1b3NCVkeHUh?=
HCC2998 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ZOItnUUN3ME22MlM1KG6P NGnqOXhUSU6JRWK=
HD-MY-Z Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTIVYpKSzVyPU[uOlghdk1? MYfTRW5ITVJ?
OS-RC-2 M1fDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvURVVKSzVyPU[uOlghdk1? MVHTRW5ITVJ?
SF126 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;LcYFKSzVyPUeuNFUhdk1? M1LIR3NCVkeHUh?=
Ca-Ski M3TPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr0TWM2OD15LkC5JI5O NIOwVGtUSU6JRWK=
NCI-H358 MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LadGlEPTB;Nz6xOkBvVQ>? NXf1PVZiW0GQR1XS
J82 NGm1WZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTdwNEGgcm0> MnThV2FPT0WU
NCI-H2342 M13Tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PQVGlEPTB;Nz62N{BvVQ>? M3jxT3NCVkeHUh?=
OVCAR-8 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjETWM2OD15Lkmgcm0> NF;5eYdUSU6JRWK=
TE-8 M1HCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYCxUmJwUUN3ME24JI5O MWLTRW5ITVJ?
ETK-1 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fRbmlEPTB;OD6wPEBvVQ>? M4nRV3NCVkeHUh?=
HAL-01 NXm1VI5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPTTWM2OD16LkKgcm0> NGXRS4NUSU6JRWK=
KYSE-150 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRThwNEegcm0> MkLKV2FPT0WU
NCI-H810 NYHROFJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETRZ3RKSzVyPUiuOVYhdk1? MX;TRW5ITVJ?
ONS-76 NWHF[Iw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwNkigcm0> M{\2V3NCVkeHUh?=
NMC-G1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnxUYlQUUN3ME24Mlc3KG6P MorRV2FPT0WU
C3A M3rOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LHd2lEPTB;OD64OEBvVQ>? MlTCV2FPT0WU
PA-1 NIT5NIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\hT2lEPTB;OD65PUBvVQ>? NVnGVItsW0GQR1XS
SH-4 NYrrSWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KwcmlEPTB;OT6wNkBvVQ>? MX;TRW5ITVJ?
EFO-27 NGW4epZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTBVGJFUUN3ME25MlA2KG6P NUHUcXVwW0GQR1XS
CAPAN-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rIXmlEPTB;OT6yN{BvVQ>? NWXET4RLW0GQR1XS
DU-145 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXXTWM2OD17LkK5JI5O NWPSUGJkW0GQR1XS
A101D NIjETpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rFemlEPTB;OT6zO{BvVQ>? MXPTRW5ITVJ?
ST486 NGfwd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK3NIFKSzVyPUmuOFEhdk1? NWrRW|NuW0GQR1XS
NCI-H1437 M3TEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTlwNEKgcm0> NFf2eJZUSU6JRWK=
HGC-27 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxfWJ2UUN3ME25MlYhdk1? NFLEN|dUSU6JRWK=
8305C MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEiwd2lKSzVyPUmuOlQhdk1? NXKwNZVTW0GQR1XS
OCUB-M NWfUXmJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfZUZk{UUN3ME2xNE4xOyCwTR?= NW[4TXZRW0GQR1XS
COLO-679 M2XCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jUbWlEPTB;MUCuNFchdk1? MnrPV2FPT0WU
Detroit562 NWSzOVB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n6RmlEPTB;MUCuOFIhdk1? Ml7FV2FPT0WU
A204 M4WyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnqV4dKSzVyPUGxMlE3KG6P M2HMeXNCVkeHUh?=
NCI-H1734 NVPEVGdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFzLkK5JI5O MVPTRW5ITVJ?
MC-CAR MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrpOpl{UUN3ME2xNU42QCCwTR?= M3z0VXNCVkeHUh?=
NCI-H2170 MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHRR5hKSzVyPUGxMlk4KG6P MXLTRW5ITVJ?
NCI-SNU-5 M2HjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33tbWlEPTB;MUKuNVMhdk1? MVfTRW5ITVJ?
HCE-T MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\xXmlEPTB;MUKuOFIhdk1? MW\TRW5ITVJ?
KYSE-180 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjGTWM2OD1zMj64NUBvVQ>? NXPqfY1DW0GQR1XS
C8166 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXSTWM2OD1zMz6wPEBvVQ>? MonQV2FPT0WU
NCI-H460 NEfUWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF|LkW0JI5O NE\kfoFUSU6JRWK=
SNU-449 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DZdWlEPTB;MUOuO|chdk1? MWfTRW5ITVJ?
MDA-MB-468 NX[0O3hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rpV2lEPTB;MUSuNVIhdk1? NF3SR5ZUSU6JRWK=
COR-L23 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qzNGlEPTB;MUSuNVMhdk1? MnXrV2FPT0WU
CTV-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrYSnJKSzVyPUG0MlE1KG6P NInqTFNUSU6JRWK=
BL-41 M1XyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXoNG52UUN3ME2xOE4{PyCwTR?= Ml;NV2FPT0WU
IGR-1 M2DEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnLVI5KSzVyPUG0MlQzKG6P NHLCc|RUSU6JRWK=
TK10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7NcGFKSzVyPUG0MlQ6KG6P MmrkV2FPT0WU
REH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjSR|VUUUN3ME2xOE42OSCwTR?= NHexcZNUSU6JRWK=
LU-139 NYDQPI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfOTWM2OD1zND61PUBvVQ>? M37vfHNCVkeHUh?=
KP-N-YS MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jhOWlEPTB;MUSuPVchdk1? NYTCXldzW0GQR1XS
PANC-10-05 NHixbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjZTWM2OD1zNT6zPEBvVQ>? NV7m[3VkW0GQR1XS
HL-60 NIHyO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj2OJZKSzVyPUG1MlY6KG6P NFrQZWFUSU6JRWK=
T84 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7TTWM2OD1zNT65OkBvVQ>? Ml20V2FPT0WU
RPMI-8226 NEPHTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn2TlRKSzVyPUG2MlAzKG6P MXzTRW5ITVJ?
UM-UC-3 M3[3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDzTWM2OD1zNj6xOkBvVQ>? MkfOV2FPT0WU
TE-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS4SYlKSzVyPUG2MlIyKG6P NXfLfHhjW0GQR1XS
CAL-148 NHnFZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLUTWM2OD1zNz6yN{BvVQ>? MkjGV2FPT0WU
BV-173 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF5LkK3JI5O M1vZOXNCVkeHUh?=
Calu-3 MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\ZVWlEPTB;MUeuNlkhdk1? NIPuNHVUSU6JRWK=
RPMI-2650 M4HP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDpTWM2OD1zNz61PUBvVQ>? Mon5V2FPT0WU
MKN45 NXHieXp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF5LkezJI5O M{K5[nNCVkeHUh?=
NUGC-3 NXPYd3RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvOdlZKSzVyPUG4MlM1KG6P MYfTRW5ITVJ?
NCI-H520 M4PM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF6Lke3JI5O MVHTRW5ITVJ?
CCRF-CEM NVPuUFcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDlTWM2OD1zOD64OUBvVQ>? MVrTRW5ITVJ?
NCI-H2405 NHjTUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDyTWM2OD1zOT6xJI5O M{HJN3NCVkeHUh?=
ES7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF7Lke2JI5O MnPJV2FPT0WU
BPH-1 NIOzfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITvT3hKSzVyPUKwMlI5KG6P NIPrbllUSU6JRWK=
SAS NYDBdoQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnYWJEzUUN3ME2yNE42KG6P NF;VZW5USU6JRWK=
HuCCT1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XlZmlEPTB;MkCuOVghdk1? MWnTRW5ITVJ?
LOUCY MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJyLk[2JI5O M4rL[3NCVkeHUh?=
NCI-H292 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjBTWM2OD1{MD63PUBvVQ>? NUCxdGdXW0GQR1XS
G-361 M2XKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m3c2lEPTB;MkGuNFchdk1? M2HnWHNCVkeHUh?=
M059J M3\jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LPR2lEPTB;MkGuNFghdk1? MUXTRW5ITVJ?
NCI-H1651 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;uTWM2OD1{MT6xNUBvVQ>? M1vzbHNCVkeHUh?=
KALS-1 M2LI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJzLkO5JI5O MYnTRW5ITVJ?
DJM-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJzLkW5JI5O M2TLNHNCVkeHUh?=
AU565 M4XRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJzLkizJI5O Mnr5V2FPT0WU
HCC38 M2XZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK0TWM2OD1{MT65OUBvVQ>? MXrTRW5ITVJ?
U251 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ{LkK3JI5O NE\TR4tUSU6JRWK=
ABC-1 M4fJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTBVYNzUUN3ME2yNk43PSCwTR?= NFSwdYpUSU6JRWK=
SK-NEP-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnTTWM2OD1{Mj65N{BvVQ>? NXnvWIxJW0GQR1XS
CESS M2DNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3pTWM2OD1{Mz6xPUBvVQ>? NGnDcG1USU6JRWK=
MIA-PaCa-2 M{DJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPkTWM2OD1{Mz6zOkBvVQ>? NFPFT4tUSU6JRWK=
SUP-T1 NV\N[2NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TmWWlEPTB;MkOuOFchdk1? NEPHdppUSU6JRWK=
L-428 NX;YXXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SwOmlEPTB;MkOuOlIhdk1? NUnBbXNNW0GQR1XS
SW954 MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n6ZmlEPTB;MkOuOlghdk1? MWLTRW5ITVJ?
HO-1-N-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u0OWlEPTB;MkOuO|chdk1? NYToNIRVW0GQR1XS
CHP-126 NInKbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJ2LkG0JI5O NVfudld5W0GQR1XS
HMV-II NVT3VolLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm3VWxKSzVyPUK0MlM1KG6P Moj6V2FPT0WU
NB10 NYOxUYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnPU3VyUUN3ME2yOE4{PyCwTR?= Mn3HV2FPT0WU
A172 NVPqOXFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETJT5JKSzVyPUK0MlcyKG6P NXLjUWRlW0GQR1XS
MONO-MAC-6 NVnNco44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ2Lki0JI5O Mn\yV2FPT0WU
NCI-H1650 NUjoUWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ3LkSgcm0> NFqzPYlUSU6JRWK=
NH-12 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXP[WI5UUN3ME2yOU42KG6P MX;TRW5ITVJ?
ML-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX4TWM2OD1{NT63OEBvVQ>? NVjw[HdIW0GQR1XS
MZ2-MEL M2SxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ4LkKyJI5O NVfreIZKW0GQR1XS
COLO-684 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH4TWM2OD1{Nj60NUBvVQ>? NVLoXWwxW0GQR1XS
HuP-T4 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjINJB5UUN3ME2yO{4{KG6P Mn;mV2FPT0WU
SW837 NHrmbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DabGlEPTB;MkeuOlIhdk1? NWPObnc1W0GQR1XS
MDA-MB-231 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT1[Wo2UUN3ME2yO{44QCCwTR?= Mm[xV2FPT0WU
KYSE-140 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn6[otMUUN3ME2yO{46OSCwTR?= M1T1UnNCVkeHUh?=
NOMO-1 M4PJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCyXI1rUUN3ME2yPE43QCCwTR?= M4HZUHNCVkeHUh?=
GP5d NGrFVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPYb4pKSzVyPUK4MlczKG6P MVHTRW5ITVJ?
COR-L105 M33RdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnad41WUUN3ME2yPU41OiCwTR?= M2KwTnNCVkeHUh?=
LS-411N M4LJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz6TWM2OD1{OT64PEBvVQ>? MYfTRW5ITVJ?
NY M17Md2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTNyLkG4JI5O NXPVS|B1W0GQR1XS
NCI-H2030 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNyLkS1JI5O MkPPV2FPT0WU
CCF-STTG1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nvZmlEPTB;M{GuOFIhdk1? NVPtOXA3W0GQR1XS
NCI-H1703 M2PzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzCUHlKSzVyPUOxMlc5KG6P NGP3VHpUSU6JRWK=
TUR MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTN{LkCzJI5O NH;teZJUSU6JRWK=
NOS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXqWW9GUUN3ME2zNk41PCCwTR?= Ml7UV2FPT0WU
A2058 M3zRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X5eWlEPTB;M{KuPFMhdk1? MnXaV2FPT0WU
LCLC-103H NHGwVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\vNGlEPTB;M{OuNlUhdk1? NIXq[4FUSU6JRWK=
NCI-H510A MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PZV2lEPTB;M{OuNlchdk1? NX\lZ3N6W0GQR1XS
BC-1 M2nFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vKd2lEPTB;M{OuO|chdk1? NHXFOGhUSU6JRWK=
SK-CO-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3pTWM2OD1|ND6wNUBvVQ>? MWLTRW5ITVJ?
A673 M1vTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnmTWM2OD1|ND6xO{BvVQ>? M1:1c3NCVkeHUh?=
VM-CUB-1 NGKydFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq3RYZKSzVyPUO0MlY6KG6P NHu0NWVUSU6JRWK=
HH NXSwc|h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zPdWlEPTB;M{WuNFYhdk1? MUDTRW5ITVJ?
CAL-27 NHTBNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfuTWM2OD1|NT6xOkBvVQ>? Mof3V2FPT0WU
NEC8 NIjhNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3j[ohKSzVyPUO1MlM4KG6P NWDONmlUW0GQR1XS
BxPC-3 M33qSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PWWmlEPTB;M{[uPVEhdk1? M3rpcXNCVkeHUh?=
SNB75 NWTCeFdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPre25KSzVyPUO3MlI1KG6P MkLoV2FPT0WU
NB13 NWPNeJRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS3TWM2OD1|OD6yN{BvVQ>? MUfTRW5ITVJ?
SK-OV-3 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSTWM2OD1|OD63OEBvVQ>? MVTTRW5ITVJ?
ME-180 NYnMPWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M363ZmlEPTB;M{iuPEBvVQ>? M1niT3NCVkeHUh?=
JiyoyeP-2003 NHLIbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:1TWM2OD1|OT6zPEBvVQ>? MUPTRW5ITVJ?
LU-134-A NHfBR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXMW2NKSzVyPUSwMlAzKG6P MUDTRW5ITVJ?
LS-123 M{LDVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPwd4lKSzVyPUSwMlI5KG6P MXzTRW5ITVJ?
COLO-800 NULLc4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nN[WlEPTB;NECuOVYhdk1? M2PXSnNCVkeHUh?=
LB831-BLC M1\YZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfEVItKSzVyPUSxMlg2KG6P MoPPV2FPT0WU
NCI-H747 M2Wyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj4R4NHUUN3ME20Nk4zQCCwTR?= MYrTRW5ITVJ?
MZ7-mel M33ONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\t[YxKSzVyPUSyMlY3KG6P MkD0V2FPT0WU
GT3TKB MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPWbGNKSzVyPUSyMlczKG6P NUHVfo9NW0GQR1XS
MOLT-16 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPjRWxqUUN3ME20N{4xPSCwTR?= M{Lm[3NCVkeHUh?=
23132-87 M1L1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vaOGlEPTB;NEOuNFUhdk1? M2DVbnNCVkeHUh?=
PF-382 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HIPGlEPTB;NESuNlIhdk1? MUPTRW5ITVJ?
ES3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXwTnVNUUN3ME20OE43KG6P NVHRT3hOW0GQR1XS
SW756 NIPEUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH5WYpoUUN3ME20OU4yPCCwTR?= M{PhTnNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
water (warmed)
混合させたのち直ちに使用することを推奨します。
52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4

CAS No. 95058-81-4
保管
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID